Developing A Drug-Protein Interactome for Identifying Potential Drug Targets In-situ
Our method reveals the interaction landscape of a given drug. We will generate a two-part biosensor inside living cells. The first part involves a genetically encoded reactive ‘beacon’. The second part is the drug of interest, synthetically modified with complementary reactivity to the beacon. When present together in cells, both parts chemically combine to form a chimeric ‘drug-beacon’, which will then report on the local protein environment of the derivatized drug by using proteomics. It can be applied to drug-treatment regimens on cells isolated from different patients, as part of personalized-drug discovery programs. With the successful outcome of this project, partner organization will get to benefit from the commercialization of this method by upscaling this technology to include more classes of drugs.